CTXR NASDAQ
Credit Risk of going bust: higher than 92% of companies Debt: 34.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.05 (down 90%), Citius Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $7.2M against a stock market value of $13.8M.
Distance to default 1.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.7M (short-term plus half of long-term), stock volatility 109.7%; Altman Z'' -8.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Cranford, NJ 07016
US
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mazur Leonard L | A-Award | 125,490 | $28.75 | 2025-08-08 |
| Mazur Leonard L | A-Award | 89,388 | $19.25 | 2025-08-08 |
| Mazur Leonard L | D-Return | 125,490 | $28.75 | 2025-08-08 |
| Mazur Leonard L | D-Return | 89,388 | $19.25 | 2025-08-08 |
| HOLUBIAK MYRON Z | A-Award | 31,373 | $28.75 | 2025-08-08 |